"Precision Medicine," also known as "Personalized Medicine," is the term used for this transformative new model of healthcare that involves the selection of appropriate therapeutics tailored to a patient’s specific disease characteristics. Diagnostic tests are major enablers of Precision Medicine because they have the potential to identify changes in each individual patient's disease. The use of that knowledge can help to treat their disease through the development of treatment strategies to target specific molecular alterations unique to that patient. Ultimately, the goal of Precision Medicine is to improve patient outcomes.
A "Precision Medicine" initiative was announced by President Obama in his January 20th, 2016, State of the Union address. President Obama said he wanted the United States to "lead a new era of medicine, one that delivers the right treatment at the right time."
Rather than the current one-size-fits-all approach, drugs will be tailored to individuals, allowing doctors to target the precise form a disease takes in any individual and avoid administering drugs that may be ineffective or even harmful.
CBM2 is making timely and important discoveries to the Precision Medicine initiative by developing new and state-of-the-art tools that can transition quickly into the clinic to provide diagnostic and prognostic information currently inaccessible to the patient due to limitations in current testing platforms. CBM2 is generating diagnostic tools that will be able to detect rare disease-associated biomarkers in blood samples, such as Liquid Biopsy, and supply important information to the clinician to dramatically improve quality of care for that patient. This is being done for a variety of diseases, such as cancer, stroke and infectious diseases to name a few.
To design, manufacture and deliver new tools to the biomedical community for utilizing liquid biopsies for disease detection and management.
Innovative and fully automated mixed-scale systems that can be programmed to enable Precision Medicine in different disease states.
Collaborative & Service Projects
The Center views collaboration and service with the biomedical community as one of its main missions. Collaboration and Service Projects serve to facilitate the dissemination of existing and new technologies emanating from the Center into the biomedical community with the inevitable goal to maximize funding potential of both the Center and external researchers through enhanced visibility. Thus, the Center is excited to accept requests to engage its personnel with those in the biomedical/biological community.
Our team of senior scientists from KU, UNC, Cornell, and LSU aims to design, manufacture and deliver new tools to the biomedical community for analyzing circulating biomarkers for disease management. These circulating biomarkers comprise a Liquid Biopsy, which can be secured from blood, urine, cerebrospinal fluid or others. These markers come in many forms as well, such as whole biological cells, cell free molecules, cell free DNA, and extracellular vesicles, exosomes.
The tools we are developing consist of devices across many different length scales that provide the ability to enrich these markers from clinical samples and then, analyze them by genotyping and sequencing the DNA/RNA content of these markers. The technology we are pioneering is highly conducive to translation into the clinical laboratory.
University of Kansas
Integrated Science Building
1567 Irving Hill Road, Room 2183
Lawrence, KS 66045